All changes for the tissue kidney (65)
Identifier
Name
Type
Tissues
Organism
Gene
Data
Actions
DAA268
solute carrier family 12 (sodium/chloride transporters), member 3
Molecular
kidney
Human
SLC12A3
16.0% Decrease Gene Expression Level
DAA286
StAR-related lipid transfer (START) domain containing 8
Molecular
kidney
Human
STARD8
14.0% Decrease Gene Expression Level
DAA901
telomere shortening
Molecular
kidney
Human
—
—
DAA277
tyrosinase-related protein 1
Molecular
kidney
Human
TYRP1
21.0% Decrease Gene Expression Level
DAA289
brain protein 44-like
Molecular
kidney
Human
BRP44L
9.0% Decrease Gene Expression Level
DAA291
chromosome 1 open reading frame 162
Molecular
kidney
Human
C1orf162
37.0% Increase Gene Expression Level
DAA263
claudin 8
Molecular
kidney
Human
CLDN8
17.0% Decrease Gene Expression Level
DAA281
coiled-coil domain containing 3
Molecular
kidney
Human
CCDC3
19.0% Increase Gene Expression Level
DAA275
complement component 1, q subcomponent, C chain
Molecular
kidney
Human
C1QC
27.0% Increase Gene Expression Level
DAA288
complement component 1, r subcomponent
Molecular
kidney
Human
C1R
21.0% Increase Gene Expression Level
DAA265
complement component 1, s subcomponent
Molecular
kidney
Human
C1S
24.0% Increase Gene Expression Level
DAA287
creatine kinase, brain
Molecular
kidney
Human
CKB
10.0% Decrease Gene Expression Level
DAA273
cytoplasmic FMR1 interacting protein 2
Molecular
kidney
Human
CYFIP2
11.0% Decrease Gene Expression Level
DAA256
defensin, beta 1
Molecular
kidney
Human
DEFB1
8.0% Decrease Gene Expression Level
DAA620
Hypertensive heart and renal disease
Pathological
heart, kidney
Human
—
SeriesMorbidity
DAA626
Essential (primary) hypertension and hypertensive renal disease
Pathological
heart, kidney
Human
—
SeriesMorbidity
DAA640
Renal failure
Pathological
kidney
Human
—
SeriesMorbidity
DAA886
Renal arteriosclerosis
Pathological
renal vasculature
Human
—
—
DAA639
Kidney diseases
Pathological
kidney
Human
—
SeriesMorbidity
DAA884
Widespread degeneration of glomerular blood vessels
Physiological
renal vasculature
Human
—
—
DAA2020
Reduction in renal function
Physiological
kidney
Human
—
—
DAA894
Interstitial fibrosis in medulla
Physiological
kidney
Human
—
—
DAA885
Renal blood flow declines
Physiological
renal vasculature
Human
—
—
DAA1062
Creatinine clearance declines
Physiological
kidney
Human
—
—
DAA881
Dietary protein required to induce renal sclerotic lesions decreases
Physiological
renal vasculature
Human
—
—
Identifier | Name | Type | Tissues | Organism | Gene | Data | Actions |
---|---|---|---|---|---|---|---|
DAA268 | solute carrier family 12 (sodium/chloride transporters), member 3 | Molecular | kidney | Human | SLC12A3 | 16.0% Decrease Gene Expression Level | |
DAA286 | StAR-related lipid transfer (START) domain containing 8 | Molecular | kidney | Human | STARD8 | 14.0% Decrease Gene Expression Level | |
DAA901 | telomere shortening | Molecular | kidney | Human | — | — | |
DAA277 | tyrosinase-related protein 1 | Molecular | kidney | Human | TYRP1 | 21.0% Decrease Gene Expression Level | |
DAA289 | brain protein 44-like | Molecular | kidney | Human | BRP44L | 9.0% Decrease Gene Expression Level | |
DAA291 | chromosome 1 open reading frame 162 | Molecular | kidney | Human | C1orf162 | 37.0% Increase Gene Expression Level | |
DAA263 | claudin 8 | Molecular | kidney | Human | CLDN8 | 17.0% Decrease Gene Expression Level | |
DAA281 | coiled-coil domain containing 3 | Molecular | kidney | Human | CCDC3 | 19.0% Increase Gene Expression Level | |
DAA275 | complement component 1, q subcomponent, C chain | Molecular | kidney | Human | C1QC | 27.0% Increase Gene Expression Level | |
DAA288 | complement component 1, r subcomponent | Molecular | kidney | Human | C1R | 21.0% Increase Gene Expression Level | |
DAA265 | complement component 1, s subcomponent | Molecular | kidney | Human | C1S | 24.0% Increase Gene Expression Level | |
DAA287 | creatine kinase, brain | Molecular | kidney | Human | CKB | 10.0% Decrease Gene Expression Level | |
DAA273 | cytoplasmic FMR1 interacting protein 2 | Molecular | kidney | Human | CYFIP2 | 11.0% Decrease Gene Expression Level | |
DAA256 | defensin, beta 1 | Molecular | kidney | Human | DEFB1 | 8.0% Decrease Gene Expression Level | |
DAA620 | Hypertensive heart and renal disease | Pathological | heart, kidney | Human | — | SeriesMorbidity | |
DAA626 | Essential (primary) hypertension and hypertensive renal disease | Pathological | heart, kidney | Human | — | SeriesMorbidity | |
DAA640 | Renal failure | Pathological | kidney | Human | — | SeriesMorbidity | |
DAA886 | Renal arteriosclerosis | Pathological | renal vasculature | Human | — | — | |
DAA639 | Kidney diseases | Pathological | kidney | Human | — | SeriesMorbidity | |
DAA884 | Widespread degeneration of glomerular blood vessels | Physiological | renal vasculature | Human | — | — | |
DAA2020 | Reduction in renal function | Physiological | kidney | Human | — | — | |
DAA894 | Interstitial fibrosis in medulla | Physiological | kidney | Human | — | — | |
DAA885 | Renal blood flow declines | Physiological | renal vasculature | Human | — | — | |
DAA1062 | Creatinine clearance declines | Physiological | kidney | Human | — | — | |
DAA881 | Dietary protein required to induce renal sclerotic lesions decreases | Physiological | renal vasculature | Human | — | — |